Abstract library

20 results for "Gherlan".
#1679 Management of Neuroendocrine Tumors in the Netherlands
Introduction: To determine optimal management of patients with pancreatic neuroendocrine tumors (pNETs), more insight in the prognosis and treatment outcomes is needed.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: M.D. Cansu Genc
#514 Cost-Effectiveness of Sunitinib in Patients (Pts) with Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET) in the Netherlands
Introduction: Sunitinib (SU) is an oral multitargeted tyrosine kinase inhibitor approved and reimbursed in the Netherlands for use in advanced/metastatic well-differentiated pNET.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Huib Scheijbeler
#1485 Validation of a Blood Neuroendocrine Tumor Gene Signature, the NETest, in a Netherlands NET Cohort
Introduction: The CgA has limitations as a monoanalyte biomarker. The introduction of a PCR-based multi-analyte analysis of 51 genes (NETest) has been proposed as more accurate.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Dr Margot Tesselaar
Authors: Tesselaar M, Korse T, Kidd M, Verbeek W, ...
#1792 Treatment and Survival of 351 Patients Diagnosed with Merkel Cell Carcinoma in 2 Melanoma and Neuroendocrine Tumor Expert-Centers in the Netherlands
Introduction: Merkel cell carcinoma (MCC) is a rare and potentially aggressive neuroendocrine carcinoma of the skin. Because of its frequency, adequate data on treatment and survival are lacking.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MSc Linde M van Veenendaal
#1418 Extra-Pulmonary Neuroendocrine Carcinomas: A National Population Based Study
Introduction: Extra pulmonary neuroendocrine carcinomas(EPNEC) are rare tumours, this implies lack of knowledge on the burden.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MSc. Jan Maarten Van Der Zwan
Keywords: EP-NEC
#333 Sporadic Hypercalcitoninemia: Thyroid Medullary carcinoma, Autoimmune Thyroiditis or GLP-1 Agonists’ Effect?
Introduction: Glucagon-like peptide 1 (GLP-1) receptor agonists’ stimulated C-cell hyperplasia and tumors in rodents, but not in humans. Calcitonin also increased in autoimmune thyroid disease.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Raluca A. Trifanescu
#78 The diagnostic and prognostic value of elevated proGRP levels in well- and moderately differentiated neuroendocrine tumors
Introduction: Chromogranin A (CgA) is the most frequently used marker in well- (grade 1) and moderately (grade 2) differentiated NETs. Although CgA is a more sensitive marker than the 5-HIAA, which was widely used until the last decade, CgA has some limitations. False-positively elevated CgA may occur in renal impairment, atrophic gastritis and during treatment of proton-pump inhibitors. Progastrin-releasing peptide (proGRP) was recently reported as a promising tumor marker for small cell lung cancer. Limited data suggests that ProGRP may be a potential tumor marker in NE tumors.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Msc Catharina M Korse
#206 Diverging Incidence and Survival Trends for Neuroendocrine Tumors due to Histological Grade
Introduction: Epidemiological data of NET are mostly classified according to the primary site of the tumor. However, a pathologic classification, irrespective of primary site, might be more informative.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MSc Catharina M Korse
#666 Ability of Tumor Markers for Predicting Future Metastatic Disease in MEN-1 Patients with a Pancreatic Neuroendocrine Tumor
Introduction: The diagnostic value of tumor markers in the follow-up of MEN-1 patients with a pancreatic neuroendocrine tumor (pNET) is unclear.
Conference: 10th Annual ENETS Conference (2013)
Category: Biomarkers
Presenting Author: MD Joanne De Laat
Keywords: MEN-1, tumor marker, pNET, SSA
#881 Web-Based Tailored Information and Support for Patients with a Neuroendocrine Tumor
Introduction: Patients with neuroendocrine tumors (NET) frequently experience physical and psychosocial complaints. Optimal patient information can form an essential aspect of supportive care. To give NET patients continuous access to information, we developed a web-based tailored information and support system.
Conference: 11th Annual ENETS Conference (2014)
Category: ...none of the below
Presenting Author: MD Grietje Bouma
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.